PL2885641T3 - Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi - Google Patents

Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi

Info

Publication number: PL2885641T3
Authority: PL; Poland
Prior art keywords: methods; predicting risk; developing hypertension; hypertension; developing
Prior art date: 2012-08-16

Application number

PL13830006T

Other languages

English (en)

Inventor

James V. Snider

Original Assignee

Critical Care Diagnostics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-08-16

Filing date

2013-08-16

Publication date

2018-04-30

2013-08-16 Application filed by Critical Care Diagnostics, Inc. filed Critical Critical Care Diagnostics, Inc.

2018-04-30 Publication of PL2885641T3 publication Critical patent/PL2885641T3/pl

Links

206010020772 Hypertension Diseases 0.000 title 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/545—IL-1
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/321—Arterial hypertension
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)

PL13830006T 2012-08-16 2013-08-16 Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi PL2885641T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261683956P	2012-08-16	2012-08-16
EP13830006.6A EP2885641B1 (en)	2012-08-16	2013-08-16	Methods for predicting risk of developing hypertension
PCT/US2013/055417 WO2014028875A1 (en)	2012-08-16	2013-08-16	Methods for predicting risk of developing hypertension

Publications (1)

Publication Number	Publication Date
PL2885641T3 true PL2885641T3 (pl)	2018-04-30

Family

ID=50100476

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL13830006T PL2885641T3 (pl)	2012-08-16	2013-08-16	Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi

Country Status (16)

Country	Link
US (3)	US9523696B2 (pl)
EP (2)	EP3282258A1 (pl)
JP (3)	JP6298466B2 (pl)
CN (2)	CN107478841A (pl)
AU (2)	AU2013302451B2 (pl)
CA (1)	CA2882133A1 (pl)
DK (1)	DK2885641T3 (pl)
ES (1)	ES2656897T3 (pl)
HK (1)	HK1250782A1 (pl)
IN (1)	IN2015DN01259A (pl)
MX (2)	MX358541B (pl)
NO (1)	NO2983845T3 (pl)
PL (1)	PL2885641T3 (pl)
RU (2)	RU2683026C2 (pl)
SG (2)	SG11201501200XA (pl)
WO (1)	WO2014028875A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002218026A1 (en)	2000-11-09	2002-05-21	The Brigham And Women's Hospital, Inc.	Cardiovascular disease diagnostic and therapeutic targets
DK3072978T3 (en)	2002-05-09	2018-09-17	Brigham & Womens Hospital Inc	: 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
DK2848938T3 (da)	2006-04-24	2017-11-13	Critical Care Diagnostics Inc	Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
PT2021796E (pt)	2006-05-01	2012-04-19	Critical Care Diagnostics Inc	Diagnóstico de doença cardiovascular
JP5526122B2 (ja)	2008-04-18	2014-06-18	クリティカルケアダイアグノスティクスインコーポレイテッド	主要有害心イベントのリスクを予測する方法
CN106620692B (zh)	2010-04-09	2021-04-09	重症监护诊断股份有限公司	可溶性人st-2抗体和分析法
US8728742B2 (en)	2011-03-17	2014-05-20	Critical Care Diagnostics, Inc.	Methods predicting risk of an adverse clinical outcome
CA2842072A1 (en)	2011-07-18	2013-01-24	James V. Snider	Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
EP3434260A1 (en)	2012-05-18	2019-01-30	Critical Care Diagnostics, Inc.	Methods for treating or predicting risk of ventricular tachyarrhythmia event
EP2884908B1 (en) *	2012-08-09	2021-11-24	Smith & Nephew, Inc.	Intra-operatively adjustable cutting guide
DK2885641T3 (da)	2012-08-16	2018-01-29	Critical Care Diagnostics Inc	Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension
JP6450679B2 (ja)	2012-08-21	2019-01-09	クリティカルケアダイアグノスティクスインコーポレイテッド	マルチマーカーリスク層別化
WO2016048388A1 (en)	2014-09-26	2016-03-31	Somalogic, Inc.	Cardiovascular risk event prediction and uses thereof
CR20170240A (es)	2014-11-10	2018-04-03	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos
JP7231326B2 (ja)	2014-11-10	2023-03-01	ジェネンテック，インコーポレイテッド	Ｉｌ－３３媒介性障害のための治療及び診断方法
US10079073B2 (en)	2014-12-11	2018-09-18	Critical Care Diagnostics, Inc.	Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en)	2014-12-11	2019-06-18	Critical Care Diagnostics, Inc.	Test apparatus and methods for ST2 cardiac biomarker
RU2677611C1 (ru) *	2018-04-16	2019-01-17	Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ)	Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда
US11551817B2 (en)	2020-01-14	2023-01-10	International Business Machines Corporation	Assessing unreliability of clinical risk prediction
PE20230252A1 (es)	2020-03-13	2023-02-07	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos de estos
US20220218292A1 (en) *	2021-01-14	2022-07-14	Apple Inc.	User interfaces for monitoring health
RU2767266C1 (ru) *	2021-05-27	2022-03-17	Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ)	Способ прогнозирования однолетнего риска неблагоприятных сердечно-сосудистых событий у мужчин после декомпенсации хронической сердечной недостаточности с сохранной фракцией выброса левого желудочка сердца и синдромом обструктивного апноэ во сне
CN114350670B (zh) *	2022-03-18	2022-06-14	北京市心肺血管疾病研究所	特异性识别可溶性st2蛋白的核酸适配体及其应用
CN115188465B (zh) *	2022-06-27	2025-09-26	深圳技术大学	急性加重的预测方法及装置、电子设备和存储介质

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001218871A1 (en)	2000-03-21	2001-10-03	Takao Arai	Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
AU2002218026A1 (en)	2000-11-09	2002-05-21	The Brigham And Women's Hospital, Inc.	Cardiovascular disease diagnostic and therapeutic targets
WO2003040691A2 (en) *	2001-11-05	2003-05-15	The Brigham And Women's Hospital, Inc.	Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
DK3072978T3 (en)	2002-05-09	2018-09-17	Brigham & Womens Hospital Inc	: 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
US20060257558A1 (en)	2003-10-31	2006-11-16	Hiroshi Nomura	Plasma polymerization of atomically modified surfaces
JP5921052B2 (ja) *	2004-12-03	2016-05-24	ロードアイランドホスピタル	アルツハイマー病の検査
DK2848938T3 (da) *	2006-04-24	2017-11-13	Critical Care Diagnostics Inc	Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
EP2021799B1 (en)	2006-04-27	2011-07-20	Critical Care Diagnostics, Inc.	Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PT2021796E (pt)	2006-05-01	2012-04-19	Critical Care Diagnostics Inc	Diagnóstico de doença cardiovascular
ES2723957T3 (es)	2006-05-02	2019-09-04	Critical Care Diagnostics Inc	Procedimiento de selección de un tratamiento basado en el diagnóstico diferencial entre enfermedad pulmonar y cardiovascular
US8147817B2 (en) *	2006-05-04	2012-04-03	The Brigham And Women's Hospital, Inc.	IL-33 in the treatment and diagnosis of diseases and disorders
GB0703514D0 (en) *	2007-02-23	2007-04-04	Univ Ulster	Use of riboflavin
US20080300798A1 (en)	2007-04-16	2008-12-04	Mcdevitt John T	Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics
CN103123359B (zh) *	2007-08-03	2015-07-29	B.R.A.H.M.S有限公司	降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用
JP5526122B2 (ja)	2008-04-18	2014-06-18	クリティカルケアダイアグノスティクスインコーポレイテッド	主要有害心イベントのリスクを予測する方法
CN102203616A (zh) *	2008-10-07	2011-09-28	B.R.A.H.M.S有限公司	用于预测初次不利事件的生物标志物
CN102472752B (zh)	2009-08-28	2015-08-19	B.R.A.H.M.S有限公司	用于不良事件的预后的降钙素原
CN106620692B (zh)	2010-04-09	2021-04-09	重症监护诊断股份有限公司	可溶性人st-2抗体和分析法
GB201013151D0 (en) *	2010-08-04	2010-09-22	Isis Innovation	Diagnostic method
US8728742B2 (en)	2011-03-17	2014-05-20	Critical Care Diagnostics, Inc.	Methods predicting risk of an adverse clinical outcome
CA2842072A1 (en)	2011-07-18	2013-01-24	James V. Snider	Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
US20130157290A1 (en) *	2011-12-16	2013-06-20	Yves Levy	Soluble st2 as a marker for disease
EP3434260A1 (en)	2012-05-18	2019-01-30	Critical Care Diagnostics, Inc.	Methods for treating or predicting risk of ventricular tachyarrhythmia event
DK2885641T3 (da)	2012-08-16	2018-01-29	Critical Care Diagnostics Inc	Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension
JP6450679B2 (ja) *	2012-08-21	2019-01-09	クリティカルケアダイアグノスティクスインコーポレイテッド	マルチマーカーリスク層別化
CA2935958A1 (en)	2014-01-10	2015-07-16	Critical Care Diagnostics, Inc.	Methods and systems for determining risk of heart failure
USD770057S1 (en)	2014-04-14	2016-10-25	Critical Care Diagnostics, Inc.	Blood test kit
USD800332S1 (en) *	2014-09-23	2017-10-17	Critical Care Diagnostics, Inc.	Blood test kit
USD800333S1 (en) *	2014-09-23	2017-10-17	Critical Care Diagnostics, Inc.	Blood test kit
US10079073B2 (en)	2014-12-11	2018-09-18	Critical Care Diagnostics, Inc.	Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en)	2014-12-11	2019-06-18	Critical Care Diagnostics, Inc.	Test apparatus and methods for ST2 cardiac biomarker

2013
- 2013-08-16 DK DK13830006.6T patent/DK2885641T3/da active
- 2013-08-16 SG SG11201501200XA patent/SG11201501200XA/en unknown
- 2013-08-16 RU RU2015108959A patent/RU2683026C2/ru active
- 2013-08-16 CN CN201710532173.1A patent/CN107478841A/zh active Pending
- 2013-08-16 AU AU2013302451A patent/AU2013302451B2/en not_active Ceased
- 2013-08-16 CN CN201380052763.4A patent/CN104737023B/zh not_active Expired - Fee Related
- 2013-08-16 CA CA2882133A patent/CA2882133A1/en not_active Abandoned
- 2013-08-16 RU RU2019107598A patent/RU2019107598A/ru unknown
- 2013-08-16 PL PL13830006T patent/PL2885641T3/pl unknown
- 2013-08-16 EP EP17191053.2A patent/EP3282258A1/en not_active Withdrawn
- 2013-08-16 EP EP13830006.6A patent/EP2885641B1/en not_active Not-in-force
- 2013-08-16 MX MX2015002061A patent/MX358541B/es active IP Right Grant
- 2013-08-16 WO PCT/US2013/055417 patent/WO2014028875A1/en not_active Ceased
- 2013-08-16 JP JP2015527668A patent/JP6298466B2/ja not_active Expired - Fee Related
- 2013-08-16 SG SG10201704311VA patent/SG10201704311VA/en unknown
- 2013-08-16 US US13/969,116 patent/US9523696B2/en active Active
- 2013-08-16 ES ES13830006.6T patent/ES2656897T3/es active Active
- 2013-08-16 MX MX2018010151A patent/MX382403B/es unknown
2014
- 2014-04-10 NO NO14716337A patent/NO2983845T3/no unknown
2015
- 2015-02-16 IN IN1259DEN2015 patent/IN2015DN01259A/en unknown
- 2015-09-08 HK HK18110132.8A patent/HK1250782A1/en unknown
2016
- 2016-12-19 US US15/382,810 patent/US10041957B2/en not_active Expired - Fee Related
2018
- 2018-02-23 JP JP2018030232A patent/JP6757757B2/ja not_active Expired - Fee Related
- 2018-08-03 US US16/054,378 patent/US20180335437A1/en not_active Abandoned
2019
- 2019-04-15 AU AU2019202597A patent/AU2019202597A1/en not_active Abandoned
2020
- 2020-08-31 JP JP2020145790A patent/JP2020196757A/ja active Pending

Also Published As

Publication number	Publication date
HK1212022A1 (en)	2016-06-03
CN104737023B (zh)	2017-07-28
SG11201501200XA (en)	2015-04-29
JP6298466B2 (ja)	2018-03-20
JP2018135330A (ja)	2018-08-30
US10041957B2 (en)	2018-08-07
RU2015108959A (ru)	2016-10-10
MX358541B (es)	2018-08-24
JP2020196757A (ja)	2020-12-10
EP3282258A1 (en)	2018-02-14
EP2885641A4 (en)	2016-03-23
US20180335437A1 (en)	2018-11-22
EP2885641A1 (en)	2015-06-24
RU2683026C2 (ru)	2019-03-26
CA2882133A1 (en)	2014-02-20
MX382403B (es)	2025-03-13
US9523696B2 (en)	2016-12-20
HK1250782A1 (en)	2019-01-11
SG10201704311VA (en)	2017-07-28
WO2014028875A1 (en)	2014-02-20
EP2885641B1 (en)	2017-11-01
DK2885641T3 (da)	2018-01-29
AU2013302451B2 (en)	2019-01-17
IN2015DN01259A (pl)	2015-07-03
AU2013302451A1 (en)	2015-03-05
CN107478841A (zh)	2017-12-15
HK1208075A1 (en)	2016-02-19
US20170219610A1 (en)	2017-08-03
MX2015002061A (es)	2015-06-05
NO2983845T3 (pl)	2017-12-16
AU2019202597A1 (en)	2019-05-02
US20140051773A1 (en)	2014-02-20
RU2019107598A (ru)	2019-03-28
JP2015526727A (ja)	2015-09-10
ES2656897T3 (es)	2018-02-28
JP6757757B2 (ja)	2020-09-23
CN104737023A (zh)	2015-06-24

Publication	Publication Date	Title
SG11201501200XA (en)	2015-04-29	Methods for predicting risk of developing hypertension
IL276488A (en)	2020-09-30	Method of predicting breast cancer prognosis
GB201102014D0 (en)	2011-03-23	Method for predicting risk of developing cancer
EP2686689A4 (en)	2014-09-03	METHODS OF PREDICTING RISK OF UNDESIRABLE CLINICAL RESULT
EP2702513A4 (en)	2014-10-22	DETERMINATION OF RECOMMENDATION DATA
EP2717100A4 (en)	2015-03-04	TONER
EP2710430A4 (en)	2014-10-22	Toner
PL2825719T3 (pl)	2016-11-30	Sposób obsługi odwiertów
EP2717099A4 (en)	2014-12-17	TONER
EP2710432A4 (en)	2014-11-12	Toner
EP2691815A4 (en)	2014-09-03	TONER
EP2710431A4 (en)	2014-11-12	TONER
EP2794330A4 (en)	2015-12-30	METHOD AND MODULE FOR DETERMINING AT LEAST ONE REFERENCE VALUE
DK2879615T3 (da)	2017-01-02	Fremgangsmåde til at bestemme sandsynlighed for brunst
SMT201900336T1 (it)	2019-07-11	Metodo di valutazione del rischio di pml
EP2753982A4 (en)	2015-06-03	TONER
GB201104556D0 (en)	2011-05-04	Biomarkers
BR112015002542A2 (pt)	2017-07-04	método de caracterização de um objeto
GB2510539B (en)	2016-04-20	Biomarkers of cancer
AP2014007806A0 (en)	2014-07-31	Method for floating
GB201215942D0 (en)	2012-10-24	Method of treatent
SG11201502998UA (en)	2015-06-29	Methods and kits for increasing or predicting oil yield
ZA201503833B (en)	2016-10-26	Method of hemoglobin-f determination
EP2780766A4 (en)	2016-06-01	DEVICES FOR QUANTIFYING TEMPORARY TIME
ZA201400950B (en)	2015-08-26	Method for predicting risk of hypertension associated with anti-angiogenesis therapy